Replimune (REPL) Accumulated Depreciation (2018 - 2021)
Replimune (REPL) posted Accumulated Depreciation of $2.6 million for Q1 2021, up 22.93% sequentially from $2.2 million in Q4 2020, and up 182.6% YoY from $937000.0 in Q1 2020.
Analysis
Replimune (REPL) Accumulated Depreciation (2018 - 2021) Analysis & Trends
Replimune has reported Accumulated Depreciation for 4 years, with the latest figure at $2.6 million in Q1 2021.
- Quarterly Accumulated Depreciation rose 182.6% year-over-year to $2.6 million in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $2.6 million (up 182.6% YoY) and the FY2021 annual result came in at $2.6 million, up 182.6% from the prior year.
- Accumulated Depreciation advanced to $2.6 million in Q1 2021 per REPL's latest filing, from $2.2 million in the prior quarter.
- Over five years, Accumulated Depreciation peaked at $2.6 million in Q1 2021 and troughed at $256000.0 in Q1 2018.
- A 4-year average of $921846.2 and a median of $488000.0 in 2019 frame the typical range for Accumulated Depreciation.
- The sharpest annual moves came in 2019 and 2020: Accumulated Depreciation soared 50.15% in 2019, then jumped 262.02% in 2020.
- Over 4 years, Accumulated Depreciation stood at $362000.0 in 2018, then jumped by 64.36% to $595000.0 in 2019, then surged by 262.02% to $2.2 million in 2020, then rose by 22.93% to $2.6 million in 2021.
- According to Business Quant data, Accumulated Depreciation over the past three periods registered $2.6 million, $2.2 million, and $1.8 million for Q1 2021, Q4 2020, and Q3 2020 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Replimune | 1.46 Bn | 1.46 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2021 | 2.65 Mn |
| Dec 31, 2020 | 2.15 Mn |
| Sep 30, 2020 | 1.75 Mn |
| Jun 30, 2020 | 1.33 Mn |
| Mar 31, 2020 | 937,000.00 |
| Dec 31, 2019 | 595,000.00 |
| Sep 30, 2019 | 488,000.00 |
| Jun 30, 2019 | 446,000.00 |
| Mar 31, 2019 | 404,000.00 |
| Dec 31, 2018 | 362,000.00 |
| Sep 30, 2018 | 325,000.00 |
| Jun 30, 2018 | 289,000.00 |
| Mar 31, 2018 | 256,000.00 |